Bristol Myers Squibb hematology chief talks COVID-19 challenges, opportunities in blood cancer therapies

Bristol Myers Squibb’s hematology group began the year integrating acquired therapies from Celgene and prepping new therapies for debut, strategizing launches and looking at ways to bolster the portfolio beyond its stronghold in multiple myeloma.